Specialty Pharmaceuticals: Solving the Encore Problem
This article was originally published in Start Up
Executive Summary
Even the most successful specialty pharmas hit a point where an in-licensing candidate has to be almost too costly in order to sustain the growth of the organization. Start-ups are trying to avoid this trap by developing capabilities that add significant value to an in-licensing candidate, or by having at the outset some approach to identifying products and niches that no one else can.
You may also be interested in...
The $500 Threshold Under Medicare
The federal government is allowing Medicare prescription drug plans to make aggressive use of four-tier formularies. A key detail is the definition of products that qualify for the fourth "specialty" tier. CMS' rules will affect price negotiations for high cost drugs.
Sention Inc.
Sention Inc. is developing discovery tools, including a proprietary whole-animal assay system, that measure the genes and proteins involved in memory consolidation. It is using that platform to identify known drugs developed for other uses, and therefore with established safety profiles, which can regulate memory consolidation.
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.